These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35725215)
1. A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411. Khademi Z; Ramezani M; Alibolandi M; Zirak MR; Salmasi Z; Abnous K; Taghdisi SM Carbohydr Polym; 2022 Sep; 292():119691. PubMed ID: 35725215 [TBL] [Abstract][Full Text] [Related]
2. FOXM1 Aptamer-Polyethylenimine Nanoplatform Coated With Hyaluronic Acid And AS1411 Aptamer For Dual-Targeted Delivery of Doxorubicin And Synergistic Treatment of Tumor Cells. Khademi Z; Yazdi KS; Ramezani M; Alibolandi M; Rezvani SA; Abnous K; Taghdisi SM J Pharm Sci; 2024 Aug; 113(8):2198-2207. PubMed ID: 38432623 [TBL] [Abstract][Full Text] [Related]
3. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells. Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of doxorubicin and aptamer against Forkhead box M1 using chitosan-gold nanoparticles coated with nucleolin aptamer for synergistic treatment of cancer cells. Khademi Z; Lavaee P; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM Carbohydr Polym; 2020 Nov; 248():116735. PubMed ID: 32919550 [TBL] [Abstract][Full Text] [Related]
5. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression. He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886 [TBL] [Abstract][Full Text] [Related]
6. Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan/hyaluronic acid/protamine polyplexes containing CRISPR-Cas9. Shirani-Bidabadi S; Mirian M; Varshosaz J; Tavazohi N; Sadeghi HMM; Shariati L Biochim Biophys Acta Gen Subj; 2023 Aug; 1867(8):130385. PubMed ID: 37230419 [TBL] [Abstract][Full Text] [Related]
7. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing. Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851 [TBL] [Abstract][Full Text] [Related]
8. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene. Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313 [TBL] [Abstract][Full Text] [Related]
9. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy. Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289 [TBL] [Abstract][Full Text] [Related]
10. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice. Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767 [TBL] [Abstract][Full Text] [Related]
11. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties. He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162 [TBL] [Abstract][Full Text] [Related]
12. Dual-targeted delivery system using hollow silica nanoparticles with H Mirzaei S; Khademi Z; Zolfaghari R; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM Drug Dev Ind Pharm; 2023 Oct; 49(10):648-657. PubMed ID: 37772892 [TBL] [Abstract][Full Text] [Related]
13. Systemic biodistribution and hepatocyte-specific gene editing with CRISPR/Cas9 using hyaluronic acid-based nanoparticles. Francis C; Wroblewska L; Pegman P; Amiji M Nanomedicine; 2022 Feb; 40():102488. PubMed ID: 34748964 [TBL] [Abstract][Full Text] [Related]
14. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector. Liu BY; He XY; Zhuo RX; Cheng SX Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194 [TBL] [Abstract][Full Text] [Related]
15. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing. Xu Y; Liu R; Dai Z Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813 [TBL] [Abstract][Full Text] [Related]
16. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors. Liu BY; He XY; Zhuo RX; Cheng SX J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905 [TBL] [Abstract][Full Text] [Related]
17. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina. Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582 [TBL] [Abstract][Full Text] [Related]
18. Development of aptamer-based inhibitors for CRISPR/Cas system. Zhao J; Inomata R; Kato Y; Miyagishi M Nucleic Acids Res; 2021 Feb; 49(3):1330-1344. PubMed ID: 33123724 [TBL] [Abstract][Full Text] [Related]
19. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503 [TBL] [Abstract][Full Text] [Related]
20. Different Methods of Delivering CRISPR/Cas9 Into Cells. Chandrasekaran AP; Song M; Kim KS; Ramakrishna S Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]